



Bioniche Pharma Media Contact:
Kara Maxwell
847.739.3249
kmaxwell@bionichepharmausa.com

Bioniche Pharma Launches Ibutilide Fumarate Injection

Lake Forest, IL, January 12, 2010 - Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals announced today the launch of Ibutilide Fumarate Injection, the generic equivalent of Corvert[®] from Pfizer Inc.

“The addition of Ibutilide Fumarate Injection further demonstrates Bioniche Pharma’s continued growth and dedication to a consistently expanding portfolio of injectables,” said George Zorich, President, US Operations for Bioniche Pharma.

Bioniche Pharma will supply Ibutilide Fumarate Injection in 0.1 mg/mL, 10mL vials.

This product has a boxed warning relating to proarrhythmic effects including potentially fatal arrhythmias (e.g., polymorphic ventricular tachycardia) and consideration for use in patients with chronic atrial fibrillation. Please [click here](#) to be directed to the complete prescribing information for this product, including the boxed warning.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets. The company’s growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.

Corvert[®] is a registered trademark of Pharmacia & Upjohn Company LLC

###